Abstract | BACKGROUND: OBJECTIVE: METHODS: RESULTS: During follow-up periods of 8-23 months (mean, 15 months), all patients showed substantial clinical improvement (n = 6) or stabilisation of symptoms (n = 3). Serum VEGF levels decreased in all patients and were normalised in five patients. Nerve conduction velocities in the median nerve increased in seven patients. There were no serious adverse effects, including thalidomide neuropathy. CONCLUSION:
|
Authors | S Kuwabara, S Misawa, K Kanai, S Sawai, T Hattori, M Nishimura, C Nakaseko |
Journal | Journal of neurology, neurosurgery, and psychiatry
(J Neurol Neurosurg Psychiatry)
Vol. 79
Issue 11
Pg. 1255-7
(Nov 2008)
ISSN: 1468-330X [Electronic] England |
PMID | 18469028
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiogenesis Inhibitors
- Anti-Inflammatory Agents
- Vascular Endothelial Growth Factor A
- Thalidomide
- Dexamethasone
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors
(pharmacology, therapeutic use)
- Anti-Inflammatory Agents
(therapeutic use)
- Dexamethasone
(therapeutic use)
- Drug Administration Schedule
- Drug Therapy, Combination
- Female
- Humans
- Male
- Middle Aged
- POEMS Syndrome
(blood, drug therapy)
- Peripheral Nervous System Diseases
(drug therapy, physiopathology)
- Thalidomide
(pharmacology, therapeutic use)
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors, blood)
|